Relating to investigational stem cell treatment.

SB 1827 regulates investigational adult stem cell treatments conducted in clinical trials within Texas. It defines such treatments as adult stem cell therapies not yet approved by the FDA, requiring clinics to obtain patient consent that explicitly states the FDA status. The bill mandates that treatments must be administered by physician-certified providers, overseen by independent ethics committees meeting specific criteria (like hospital affiliation or accreditation), and provided only in approved settings such as licensed hospitals, medical schools, or outpatient facilities. These requirements aim to standardize oversight for experimental stem cell therapies while ensuring patients are informed about the unapproved nature of the treatment.